BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), an organization digitizing biomarker evaluation to advance the science of precision well being, right now introduced that its Simoa® technology has been utilized in analysis research to detect the SARS-CoV-2 virus in serum/plasma, dried blood microsamples (DBS) and saliva samples obtained from polymerase chain response (PCR)+ COVID-19 sufferers. Revealed in Nature Communications, the analysis examine of those applied sciences affords additional proof that non-invasive antigen detection in blood or saliva samples, together with from asymptomatic and pre-symptomatic people, can function an vital complement to testing of nasal and nasopharyngeal (NP) swab samples. Along with the advantages of detecting COVID-19 throughout the pre-symptomatic window when transmissibility is thought to be highest, measuring viral load in blood could also be notably related within the context of medical research, as an indicator of illness severity or development, and doubtlessly of therapeutic efficacy.
“Regardless of the speedy proliferation of COVID-19 testing, the worldwide group continues to wrestle to beat essential challenges with the accuracy, value and availability of diagnostic assessments, and with entry to analysis instruments that would assist to allow a extremely tailor-made strategy to COVID-19 affected person care,” mentioned Kevin Hrusovsky, Chairman, Chief Govt Officer and President, Quanterix and Founder, Powering Precision Well being (PPH). “Whereas vaccine deployment continues at an aggressive tempo, COVID-19 testing and medical analysis instruments will stay a world precedence within the months to return. Extremely delicate measurements of viral antigen and the adaptive immune response from pattern varieties appropriate for assortment at point-of-care settings and at house may help facilitate international public well being efforts to curtail viral unfold and speed up remedy improvement medical analysis packages.”
Whereas present PCR-based testing stays the gold normal for COVID-19 detection, issues have been raised with respect to false negatives related to nasal and NP swabs, notably in asymptomatic and pre-symptomatic sufferers. In line with information revealed within the Annals of Internal Medicine, on day 5 of an infection – the median time for symptom onset and the height of viral transmission – molecular assessments present a 38 % likelihood of manufacturing a false consequence. Furthermore, PCR-based provide chains have been strained by elevated testing calls for, requiring the necessity to consider new testing paradigms.
Harnessing the high-sensitivity and specificity of the Simoa HD-X AnalyzerTM to quantitate the SARS-CoV-2 nucleocapsid protein and anti-SARS-CoV-2 spike IgG instantly within the varied pattern matrices on this analysis check, which is allowed to be used with NP swabs, however not but licensed by the FDA for emergency use with saliva or DBS samples, the analysis staff noticed a greater than 90 % optimistic share settlement (PPA) of COVID-19 optimistic sufferers and a greater than 98 % destructive % settlement (NPA) in all matrices inside seven days of a optimistic PCR check, utilizing pattern cohorts which included each asymptomatic and symptomatic sufferers. The analysis additionally demonstrates an inverse correlation between nucleocapsid protein clearance and a rise in SARS-CoV-2 anti-spike IgG in all matrices, suggesting that an early and sturdy IgG response alleviates extreme illness outcomes, even when excessive ranges of viral nucleocapsid protein are initially current.
“The impression of the COVID-19 pandemic will proceed to reverberate globally within the months and years forward.” continued Hrusovsky. “With applied sciences like Simoa, which may measure the focus of viral proteins in blood and saliva samples obtained non-invasively, new pathways might grow to be obtainable to broaden entry to correct and dependable testing, and to increase our understanding of COVID-19 biology. When mixed with extremely delicate Simoa assays to measure biomarkers of irritation and neurodegeneration, we will start to unravel the mysteries of COVID-19 an infection, together with the estimated 30% of infections that progress to ‘Lengthy COVID’, and speed up improvement of efficient remedy paradigms. We’re elated by the outcomes of this analysis and proceed to assist the worldwide scientific group of their tireless efforts to deal with the pandemic.”
The outcomes introduced within the Nature Communications publication have been obtained utilizing Analysis Use Solely (RUO) assays from Quanterix. For particulars on Simoa assays which have obtained Emergency Use Authorization, please go to https://www.quanterix.com/covid/.
To study extra about Quanterix’ expertise, go to https://www.quanterix.com/simoa-technology/.
Quanterix is an organization that’s digitizing biomarker evaluation with the purpose of advancing the science of precision well being. The corporate’s digital well being answer, Simoa, has the potential to vary the best way wherein healthcare is offered right now by giving researchers the flexibility to intently look at the continuum from well being to illness. Quanterix’ expertise is designed to allow a lot earlier illness detection, higher prognoses and enhanced remedy strategies to enhance the standard of life and longevity of the inhabitants for generations to return. The expertise is presently getting used for analysis purposes in a number of therapeutic areas, together with oncology, neurology, cardiology, irritation and infectious illness. The corporate was established in 2007 and is positioned in Billerica, Massachusetts. For extra info, please go to https://www.quanterix.com.
This press launch accommodates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. Phrases comparable to “might,” “will,” “anticipate,” “plan,” “anticipate,” “estimate,” “intend” and comparable expressions (in addition to different phrases or expressions referencing future occasions, circumstances or circumstances) are supposed to establish forward-looking statements. Ahead-looking statements on this information launch are primarily based on Quanterix’ expectations and assumptions as of the date of this press launch. Every of those forward-looking statements includes dangers and uncertainties. Elements that will trigger Quanterix’ precise outcomes to vary from these expressed or implied within the forward-looking statements on this press launch are mentioned in Quanterix’ filings with the U.S. Securities and Trade Fee, together with the “Threat Elements” sections contained therein. Besides as required by regulation, Quanterix assumes no obligation to replace any forward-looking statements contained herein to mirror any change in expectations, at the same time as new info turns into obtainable.